EP462 Value of tumor markers and pelvic mass diameter in differential diagnosis of peritoneal carcinomatosis

In the diagnosis of ovarian tumors, with the most frequent gystotypes specific to childhood and adolescence, is widely used of tumor markers tests: alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG) and Ca-125. Features of the development of malignancies in children restrict of tumor markers tests in clinical practice. At the same time there are no tumor marker with 100 % specificity for the tumor. The article describes the clinical cases of 13-year-old female patient with appendicular infiltrate and secondary right adnekstumor and 14-year-old girl with hematogenous disseminated tuberculosis and salpingooophorities. The levels of Ca-125 and was an increased in both cases: in the first - to 39.41 IU/ml, in the second - up to 928.1 IU/ml. Thus, it was confirmed that the increase of serum concentration of CA-125 were in direct proportion to the pathological “irritation” of peritoneal serosa. In fact, the Ca-125 had the feature of acute phase proteins, so, its tumor specificity was low. Therefore the use of tumor marker test for Ca-125 is not always makes more easy task of differential diagnosis of the nature of the tumor mass pelvic in girls.

Download Full-text

Little Clinical Relevance of Ca125, Cea and Ca125/Cea Ratio for the Differential Diagnosis of Ovarian and Non- Ovarian Carcinomatosis

Women Health Care and Issues ◽

10.31579/2642-9756/064 ◽

2021 ◽

Vol 4 (5) ◽

pp. 01-07

Author(s):

Carmen Manuela Tauste Rubio

Keyword(s):

Ovarian Cancer ◽

Differential Diagnosis ◽

Peritoneal Carcinomatosis ◽

Tumor Markers ◽

Venous Blood ◽

Area Under The Curve ◽

Poor Performance ◽

Final Diagnosis ◽

Ca 125 ◽

Peritoneal Cancer

Background In women, peritoneal cancer is commonly associated to epithelial ovarian cancer. Ovarian peritoneal carcinomatosis patient survival appears to be better in comparison to other peritoneal Malignancies, e.g., colorectal neoplasms or mesotheliomas. Here, we aim to analyze the value of CA125, CEA, CA125/CEA ratio (CCR) tumor markers as preoperative tools for the diagnosis ovarian cancer. Material and methods: From 2005-2008, we recruit prospectively patients admitted to the Navarre Hospital Complex Gynecological service with peritoneal carcinomatosis and suspicion of ovarian cancer origins. The final diagnosis of ovarian cancer carcinomatosis or other malignancies was obtained through Biopsy or cytology. CA 125, CEA and CCR were determined from preoperative venous blood Samples. We compared the tumor markers values between groups of ovarian cancer carcinomatosis and non-ovarian cancer carcinomatosis and calculate the receiver operating curves (ROC) for CA 125, CEA and CCR. Results From 250 patients with suspicion of having ovarian peritoneal carcinomatosis, only 86.4% of the Cases were finally diagnosis of ovarian cancer. Sensitivities of CA125 > 35 mg/dL, CEA < 5 ngr/mL, and CCR > 25 were 95.5%, 91.9%, and 93.6% with specificities of 4.6%, 40.9% and 40.0%, respectively. ROC displayed poor performance for CA125 and CEA for detecting ovarian peritoneal carcinomatosis patients (area under the curve (AUC): 0.69 and 0.63, respectively) while ROC analysis of CCR showed better results (AUC: 0.74). Conclusions: CCR is somehow useful to differentiate between ovarian and non-ovarian peritoneal carcinomatosis patients in comparison with CA125 and CEA alone, although without sufficient specificity for improving the differential diagnosis.

Download Full-text

Assessment of a panel of tumor markers for the differential diagnosis of benign and malignant effusions by well-based reverse phase protein array

Diagnostic Pathology ◽

10.1186/s13000-015-0290-4 ◽

2015 ◽

Vol 10 (1) ◽

Cited By ~ 3

Author(s):

Till Braunschweig ◽

Joon-Yong Chung ◽

Chel Hun Choi ◽

Hanbyoul Cho ◽

Qing-Rong Chen ◽

...

Keyword(s):

Differential Diagnosis ◽

Tumor Markers ◽

Protein Array ◽

Reverse Phase Protein Array ◽

Reverse Phase ◽

Phase Protein ◽

Malignant Effusions

Download Full-text

The Utility of Preoperative Tumor Markers in Peritoneal Carcinomatosis from Primary Appendiceal Adenocarcinoma: an Analysis from the US HIPEC Collaborative

Journal of Gastrointestinal Surgery ◽

10.1007/s11605-021-04953-y ◽

2021 ◽

Author(s):

Nadege Fackche ◽

Ryan K. Schmocker ◽

Boateng Kubi ◽

Jordan M. Cloyd ◽

Ahmed Ahmed ◽

...

Keyword(s):

Peritoneal Carcinomatosis ◽

Tumor Markers ◽

Appendiceal Adenocarcinoma ◽

The Us

Download Full-text

Detection of Classic Serum Tumor Markers (CSTMs) Group Benefits to Differential Diagnosis and Disease Assessment of UTUC

10.21203/rs.3.rs-249078/v1 ◽

2021 ◽

Author(s):

Jun-wei PAN ◽

Fang-xiu / LUO ◽

Xing-wei / JIN ◽

Wei-chao TU ◽

Xian-jin WANG ◽

...

Keyword(s):

Differential Diagnosis ◽

Tumor Markers ◽

Disease Assessment ◽

Serum Tumor Markers ◽

Test Strategy ◽

Abnormal Rate ◽

Tumor Load ◽

Group A ◽

Relationship Of ◽

Positive Results

Abstract Background: To explore the potential relationship of changes in classic serum tumor markers (CSTM) with differential diagnosis and disease assessment of upper tract urothelial carcinoma (UTUC).Methods: 60 UTUC (56 operated), 44 RCCC and 36 NTHN, were included into this retrospective analysis. The initial classic serum tumor markers (CSTMs), including CA242, CA199, CA125, CEA, AFP, SCC and CA724, were compared among the three groups. The preoperative, 1 month postoperative and 1 year postoperative/PD parameters (value and abnormal rate) of CSTMs were compared in UTUC group. A recommend test strategy was given and rechecked. The pathological manifestations of tumoral tissues and paracancerous tissues were analyzed.Results: The value of CA242, CA199 and CEA were higher in UTUC than in RCCC. The value of CEA was higher in UTUC than in NTHN. The value of CA199 and CEA were higher in UTUC than in RCCC+NTHN. The AR of CA199, CEA, SCC and CA724 were higher in UTUC than in RCCC. The AR of CEA and CA724 were higher in UTUC than in NTHN. The AR of CA199, CEA, SCC and CA724 were higher in UTUC than in RCCC+NTHN. The preoperative value of CA242 and CA199 were higher than 1 month postoperative ones in UTUC. The 1 year postop/PD value of CA242 and AFP were higher than 1 month postoperative ones in UTUC. For postop PD patients, the value during PD of CA242, CA199 and AFP were higher than 1 month postop ones. The preoperative AR of CA199 and CEA were higher than 1 month postoperative ones in UTUC. The recommended test strategy was given: CA242+CA199+CEA+AFP+SCC+CA724, and was rechecked. The P values were almost the lowest and the positive results covered all the comparisons. In 56 operated cases, the NAC in CSTMs by the recommended test strategy was statistically related with the tumor load. It appeared positive labelling by Ab of CA199, CA125, CEA, AFP and CA724 in UTUC tissues, while negative in paracancerous tissues.Conclusions: CSTMs may help to make differential diagnosis and disease assessment of UTUC. Group test (CA242+CA199+CEA+AFP+SCC+CA724) was recommended and more valuable.Trial registration: Not applicable

Download Full-text

Circulating tumor DNA as a prognostic factor in peritoneal carcinomatosis after hyperthermic intraperitoneal chemotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.e16280 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. e16280-e16280

Author(s):

Zongyuan Li ◽

Xiaolin Pu ◽

Hua Jiang

Keyword(s):

Peritoneal Carcinomatosis ◽

Tumor Markers ◽

Intraperitoneal Chemotherapy ◽

Hyperthermic Intraperitoneal Chemotherapy ◽

Peritoneal Cancer Index ◽

Circulating Tumor Dna ◽

Plasma Samples ◽

Peritoneal Cancer ◽

Time Points ◽

Tumor Dna

e16280 Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) is the main treatment for peritoneal carcinomatosis (PC).However, It is still a major problem to predict the efficacy of HIPEC. Some studies have shown that peritoneal cancer index (PCI) can be used to predict the efficacy of HIPEC, but the invasiveness and inaccuracy are shortcomings. Therefore, we need a minimally invasive and accurate prediction biomarker. Many studies have confirmed that circulating tumor DNA (ctDNA) can accurately predict the efficacy and prognosis of various solid tumors. This study aimed to evaluate the predictive value of ctDNA from ascites and plasma for HIPEC. Methods: Eligible PC patients should be defintive diagnosed by pathology or cytology. Each patient was treated with HIPEC for 4 times, with an interval of 3 days each time. Plasma and ascites samples were collected before HIPEC and after the last HIPEC. All samples were detected by next generation sequencing (NGS). The molecular tumor burden index (mTBI) and main clone variant allele fraction (VAF) changes were used as the prediction indexes of efficacy. In addition, The changes of common tumor markers such as CEA during the same period were used as controls. Results: A total of 19 patients with PC were enrolled from November 2018 to January 2020. Firstly, the mTBI changes of 14 patients whom had plasma samples at two time points (baseline and postHIPEC)were analyzed. Among them, 3 patients had no gene mutation were detected in two time points. There were significant differences in mTBI before and after HIPEC in the remaining 11 patients (Wilcoxon， p = 0.026). the median Ascites progression free survival (PFS) was 3.35 months (95% CI: 2.34 – 5.13 months), and the median overall survival (OS) was 5.93 months (95% CI: 4.93 – 11.17 months). The mTBI decline was significantly positively correlated with ascites PFS (Spearman r = 0.673, p = 0.023) and moderately positively correlated with OS (Spearman r = 0.510, p = 0.109). The highest VAF in plasma samples was defined as the main clone mutation. The main clone VAF decline was moderately positively correlated with ascites PFS (Spearman r = 0.588, p = 0.057) and slightly positively correlated with OS (Spearman r = 0.386, p = 0.241). As the controls, We found that the common tumor markers decline was no correlated with ascites PFS(Spearman r = 0.091, p = 0.790) and OS (Spearman r = 0.287, p = 0.396). We further analyzed the correlation of VAF between ascites and plasma co-mutation genes in 12 patients. The VAF of co-mutated genes in plasma and ascites was positively correlated (Spearman r = 0.794, p = 0.001). Conclusions: Plasma ctDNA can be used as a biomarker for predicting the efficacy of HIPEC for peritoneal carcinomatosis, and its accuracy is significantly higher than comon tumor markers. However, a larger sample size study are needed to validate our results.

Download Full-text